Metrion Biosciences is a leading contract research organisation (CRO) that offers highly specialised services required by pharmaceutical and biotechnology companies developing new therapeutics targeting an important group of protein structures known as ion channels, which are widespread throughout the body.
The company assists its clients in investigating how their drug candidates modulate a target ion channel to treat a range of conditions, including pain, epilepsy, anxiety, cystic fibrosis, and autoimmune disorders. Metrion also conducts safety testing to identify any unintended interactions of drugs with ion channels that could potentially cause side effects in patients.
The Metrion team are highly regarded in the drug discovery industry and are ideally placed to capitalise on an increasing understanding of ion channel biology and the resulting heightened interest in therapeutics targeting these channels. Maven has a strong track record of backing life science businesses such as BioAscent, another CRO, which has performed very strongly since the Maven VCTs first invested. I am very much looking forward to working with Andy and his team and to drawing on Maven’s experience with similar life science businesses and many other SMEs to help scale this exciting business.
David Milroy, Partner at Maven
Meet the lead executive(s)
Subscribe for email updates
